News...

CorDynamics Addresses Current Market Conditions with Affordable Cardiovascular Safety and Discovery Solutions

Chicago, Illinois (March 2009) — Over the years CorDynamics has provided clients with proven solutions for their cardiovascular safety and discovery questions.

“We’ve built our brand and client base on delivering decision-enabling isolated heart and screening telemetry results in a matter of days,” says Dr. Michael Gralinski, CorDynamics CEO. “These inherently affordable models maximize return on outsourcing spending at a time when R&D budgets have been cut throughout the biotech and pharmaceutical industry.”

CorDynamics, Inc. is a comprehensive contract research organization and consulting group focused on examining the cardiovascular effects of emerging drug candidates. The company provides support with discovery and preclinical safety pharmacology studies along with lead optimization screening and consulting for more than 100 biopharmaceutical clients.

“CorDynamics also offers full-service GLP assessments needed for lead interrogation and regulatory submissions,” says Gralinski. “Coupling our laboratories with our growing consulting operation, we truly are a ‘one-stop shop’, and our clients have leveraged that to their advantage.”

To learn more about the company, please visit our website at www.cordynamics.com. To schedule a private consultation with Dr. Gralinski please contact us at mrg@cordynamics.com.

Contact:
Michael R. Gralinski, Ph.D., CEO
mrg@cordynamics.com
www.cordynamics.com